-+ 0.00%
-+ 0.00%
-+ 0.00%

JP Morgan Maintains Overweight on Royalty Pharma, Raises Price Target to $62

Benzinga·08/07/2026 16:46:34
Listen to the news
JP Morgan analyst Chris Schott maintains Royalty Pharma (NASDAQ:RPRX) with a Overweight and raises the price target from $58 to $62.